Translating Neuroimmunological Mechanisms into Clinically Effective
Neurodegenerative Targeting Therapeutics

More and more pharma and biotech companies are investing in research focused on neuroimmunology and neuroinflammation’s relation to neurodegenerative diseases in the challenge to develop clinically effective therapeutics.

The 2nd Neuroimmunology Drug Development Summit’s agenda has specifically designed alongside neuroimmunology experts from the likes of Denali, AbbVie and Biogen to help these drug developers to overcome their translational challenges and successfully translate their drug candidates into the clinic.

Immerse yourself in the field’s cutting-edge scientific advances and take this unrivaled opportunity to join over 23 expert industry speakers and over 80 drug developers from the neuroimmunological community for over 7 hours of dedicated networking time and 2 deep-dive workshops.

To find out more and view the full speaker line-up, download the full event guide.

25 World-Class Speakers Including:

Anindya Bhattacharya

Scientific Director


David Hansen



Dimitry Ofengeim

Neuroinflammation-Lab Head


Jane Osbourn

Chief Scientific Officer


Johan Luthman

Executive Vice President, Research & Development


Malu Tansey

Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center

The University of Florida College of Medicine

Maria Carrillo

Chief Science Officer

Alzheimer’s Association

Richard Ransohoff

Venture Partner

Third Rock Ventures

Robert Paul

Chief Medical Officer


Sue Bruhn

Chief Executive Officer & President

Tiaki Therapeutics

“Teriffic meeting and glad to have it on my radar” - Brett Adams, Vice President, Magnolia Neurosciences
"Very focused meeting, that accomplished a lot in two days. The presentations were high quality and organised into interesting sessions" - Sally Ishizaka, Senior Director, Eisai
'Excellent meeting! I learned a lot' - Gayathri Ramaswamy, Associate Director, Biogen

Other Events in the World CNS Series: